12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Mon, 14 Jul 2025 18:01:46 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Server: cloudflare [5] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [6] => Vary: Accept-Encoding [7] => X-Powered-By: PHP/7.4.33 [8] => Cache-Control: no-cache, private [9] => X-Frame-Options: SAMEORIGIN [10] => X-Xss-Protection: 1; mode=block [11] => X-Content-Type-Options: nosniff [12] => Referrer-Policy: no-referrer-when-downgrade [13] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=C5S0Yjeu2HdWirX2b8SD5tRg4YMGxrgzJ%2BXbeDITIt0ozmMOSeZWb0o%2By8Ye0k4Bq2c0P4gHwacD8UgqQ2l12O9bAmfpDWPmtAfao4w%3D"}]} [14] => Cf-Cache-Status: DYNAMIC [15] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [16] => Server-Timing: cfEdge;dur=3,cfOrigin;dur=4 [17] => Set-Cookie: UpalLiveSession=eyJpdiI6IitWRndUYVdTVHdIbWpyb2d4U2l5NWc9PSIsInZhbHVlIjoiMG5hdU9HVXNGODB3SmE0bk9Ha1JPYlBwUEtwS0VhZXBUVTZqTFwvc2pxTDVGN2Q5aVNTMjhpUHdyZGxEWWlTVGt1Y2ZiTE0zcjhGQmlHVkl2NFM1RDRRPT0iLCJtYWMiOiIyNGVmM2VhOTkxMzk1ZGRiNmZlZWJiOGFiMDFjMzdjN2I5MTc2OGM0ZjhhNzE0NjNmYjY0MTVhODVmMGZmNDgzIn0%3D; HttpOnly; Path=/; Max-Age=94608000; Expires=Thu, 13 Jul 2028 17:51:09 GMT [18] => CF-RAY: 95f2ed611d6e4a14-KUL [19] => alt-svc: h3=":443"; ma=86400 ) 789

 

 

美国食品及药物管理局（FDA）宣布批准了第一款用于治疗小儿脊髓性肌萎缩症（SMA）的基因疗法Zolgensma。Zolgensma由AveXis公司研发，2018年4月，诺华收购了AveXis，并获得了该基因疗法。SMA是一种罕见的遗传性疾病，患儿用于编码运动神经元生存蛋白（SMN）的基因突变，因而出现进行性肌肉无力、瘫痪等症状，严重时，在2岁时死亡。

Zolgensma通过单次静脉注射，向患儿SMN基因的功能性拷贝，从而通过持续的SMN蛋白表达来阻止疾病进展。Zolgensma也成为FDA批准的首款用于治疗SMA的基因疗法。诺华将Zolgensma的售价定为212万美元，堪称‘史上最贵药物’。

---

// // // //